Sign Up Today and Learn More About Tute Genomics Stock
Invest in or calculate the value of your shares in Tute Genomics or other pre-IPO companies through EquityZen's platform.
About Tute Genomics Stock
Founded
2012
Headquarters
Provo, UT, US
Total Funding
7.7M
Industries
Software, Science and Engineering, Health Care
Tute Genomics is a cloud-based clinical genome interpretation platform that enables researchers and clinicians to utilize human genome data for scientific discovery and individualized treatment. The cost of whole genome sequencing is dropping rapidly and we are at the beginning of a genomics revolution. As genome sequencing becomes standard practice for both clinicians and researchers, the need for user-friendly, accurate and rapid data analysis becomes the major barrier to making important diagnoses and discoveries. To meet this demand, Tute Genomics has developed the most advanced analytical methods for genome analysis by incorporating proprietary machine-learning algorithms into a cloud based application that allows researchers to analyze & interpret entire human genomes and discover genes and biomarkers at an unprecedented rate. Tute is opening a new door by helping researchers and clinicians interpret genetic variants and find disease-related genes. Tute is a robust successor to ANNOVAR, the most widely used genome annotation & interpretation technology with over 800 scientific publications.
Tute Genomics Management
Leadership team at Tute Genomics
CEO
Reid Robison
Sr Front End Engineer
Tony Lefler
Join now and verify your accreditation status to gain access to:
- Tute Genomics current valuation
- Tute Genomics stock price
- Available deals in Tute Genomics and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
Trading Tute Genomics Stock
How to invest in Tute Genomics stock?
Accredited investors can buy pre-IPO stock in companies like Tute Genomics through EquityZen funds. These investments are made available by existing Tute Genomics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Tute Genomics stock?
Shareholders can sell their Tute Genomics stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
